Bristol Myers Squibb Announced Earlier., Investigational LPA1 Antagonist Reduces Rate Of Lung Function Decline In Progressive Pulmonary Fibrosis Cohort Of Phase 2 Study
Portfolio Pulse from Charles Gross
Bristol Myers Squibb (NYSE:BMY) announced results from a Phase 2 study of BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist for patients with progressive pulmonary fibrosis. The study showed that the drug reduced the rate of lung function decline by 69% compared to placebo. The data will be presented at the European Respiratory Society 2023 International Congress.
September 10, 2023 | 12:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Phase 2 study results show that BMS-986278, a potential first-in-class drug, significantly reduces lung function decline in patients with progressive pulmonary fibrosis.
The positive results from the Phase 2 study of BMS-986278 indicate that the drug could be a potential first-in-class treatment for progressive pulmonary fibrosis. This could lead to increased revenues for Bristol Myers Squibb if the drug is approved and successfully commercialized. Therefore, the news is highly relevant and important for BMY investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100